5-(3-methylbut-2-enoxy)-5-oxo-2-[2-(phenylmethoxycarbonylamino)-1,3-thiazol-4-yl]pent-2-enoic acid

We are 5-(3-methylbut-2-enoxy)-5-oxo-2-[2-(phenylmethoxycarbonylamino)-1,3-thiazol-4-yl]pent-2-enoic acid CAS:115065-79-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:
5-(3-methylbut-2-enoxy)-5-oxo-2-[2-(phenylmethoxycarbonylamino)-1,3-thiazol-4-yl]pent-2-enoic acid
CAS.NO:115065-79-7
Synonyms:PHE
2-Pentenedioic acid, 2-[2-[[(phenylmethoxy)carbonyl]-  amino]-4-thiazolyl]-, 5-(3-methyl-2-buten-1-yl) ester
Molecular Formula:C21H22N2O6S
Molecular Weight:430.47400
 
Physical and Chemical Properties:
Density:1.329
Index of Refraction:1.618
 
Specification:
Appearance:Off-white to pale yellow powder
Purity:≥99.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:For the synthesis of ceftibuten

5-(3-methylbut-2-enoxy)-5-oxo-2-[2-(phenylmethoxycarbonylamino)-1,3-thiazol-4-yl]pent-2-enoic acid


Related News: In a stringent xenograft model of disseminated lymphoblastic leukemia, FT819 demonstrated enhanced tumor clearance and control of leukemia as compared to primary CAR19 T cells.N-(5-Chloro-2-methylphenyl)-3-hydroxynaphthalene-2-carboxamide It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing.94-99-5 Characteristic APIs are usually more complex in structure, and their synthesis involves a variety of technologies such as chiral synthesis, green synthesis, and catalysis, which requires high research and development capabilities in the production process of API companies.864759-63-7 The second is known as the excipient, which is the inactive substance that serves as the vehicle for the API itself.Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow become dysfunctional and thus produce an inadequate number of circulating blood cells.

Related Products
Product Name
toluene-4-sulfonic acid View Details
1-Hydroxypyrene View Details
4-mercapto-4-methylpentan-2-one View Details
3-Amino-3-azabicyclo[3,3,0]octane manufacturer Diethylphosphorodithioate manufacturer 4-Bromo-3-(trifluoromethyl)phenol manufacturer 2-Methyl-4-nitropyridine manufacturer Oxalyl Chloride manufacturer